Evaluation of antiplatelet effects of ticlopidine in cats

American Journal of Veterinary Research

Volumn 65, Issue 3, 2004, Pages 327-332

  Hogan, Daniel F ^a   Andrews, Dina A ^a   Talbott, Kristen K ^a   Green, Henry W ^a   Ward, Michael P ^a   Calloway, Betsy M ^b  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; COLLAGEN; SEROTONIN; TICLOPIDINE;

ANIMAL EXPERIMENT; ANOREXIA; ANTICOAGULATION; ARTICLE; BLEEDING TIME; CAT; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG MECHANISM; LEUKOCYTE COUNT; MALE; MOUTH MUCOSA; NEUTROPHIL; NONHUMAN; SEROTONIN RELEASE; STATISTICAL ANALYSIS; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; VOMITING;

ADENOSINE DIPHOSPHATE; ANALYSIS OF VARIANCE; ANIMALS; ANOREXIA; CATS; COLLAGEN; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; SEROTONIN; TICLOPIDINE; VOMITING;

ANIMALIA; FELIS CATUS;

EID: 1542725034     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2004.65.327     Document Type: Article

References (37)

1. Harpster NK. Feline myocardial diseases. In: Kirk RW, ed. Current veterinary therapy IX. Philadelphia; WB Saunders Co, 1986; 380-388.
2. Bonagura JD, Fox PR. Restrictive cardiomyopathy. In: Bonagura JD, ed. Kirk's current veterinary therapy XII. Philadelphia: WB Saunders Co, 1995;863-867.
3. Smith SA, Tobias AH, Jacob KA, et al. Arterial thromboembolism in cats: acute crisis in 127 cases (1992-2001) and long-term management with low-dose aspirin in 24 cases. J Vet Intern Med 2003; 17:73-83.
4. Helenski CA, Ross JN. Platelet aggregation in feline cardiomyopathy. J Vet Intern Med 1987;1:24-28.
5. Welles EG, Boudreaux MK, Crager CS, et al. Platelet function and antithrombin, plasminogen, and fibrinolytic activities in cats with heart disease. Am J Vet Res 1994;55:619-627.
6. Schaub RG, Meyers KM, Sande RD, et al. Inhibition of feline collateral vessel development following experimental thrombotic occlusion. Circ Res 1976;39:736-743.
7. Butler HC. An investigation into the relationship of an aortic emboli to posterior paralysis in the cat. J Small Anim Pract 1971; 12:141-158.
8. Olmstead ML, Butler HC. Five-hydroxytryptamine antagonists and feline aortic embolism. J Small Anim Pract 1977;18:247-259.
9. Pion PD. Feline aortic thromboemboli: t-PA thrombolysis followed by aspirin therapy and rethrombosis. Vet Clin North Am Small Anim Pract 1988;18:262-263.
10. Laste NJ, Harpster NK. A retrospective study of 100 cases of feline distal aortic thromboembolism: 1977-1993. J Am Anim Hosp Assoc 1995;31:492-500.
11. Saltiel E, Ward A. Ticlopidine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states. Drugs 1987;34:222-262.
12. Gent M, Blakely JA, Easton JD, et al. The Canadian American ticlopidine study (CATS) in thromboembolic stroke. Lancet 1989;1:1215-1220.
13. Hass WK, Easton JD, Adams HP Jr, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989;321:501-507.
14. Gryglewski RJ, Korbut R, Swies J, et al. Thrombolytic action of ticlopidine: possible mechanisms. Eur J Pharmacol 1996;308:61-67.
15. Kuzniar J, Splawinska B, Malinga K, et al. Pharmacodynamics of ticlopidine: relation between dose and time of administration to platelet inhibition. Int J Clin Pharmacol Ther 1996;34:357-361.
16. McTavish D, Faulds D, Goa KL. Ticlopidine: an updated review of its pharmacology and therapeutic use in platelet dependent disorders. Drugs 1990;40:238-259.
17. Goyan JE. Ticlopidine: quo vadis? Adverse reactions in man. Agents Actions Suppl 1984;15:116-125.
18. Parker MT, Collier LL, Kier AB, et al. Oral mucosal bleeding times of normal cats and cats with Chediak-Higashi syndrome or Hageman trait (factor XII deficiency). Vet Clin Pathol 1988;17:9-12.
19. Savi P, Laplace MC, Maffrand JP, et al. Binding of [3H]-2-methylthio ADP to rat platelets - effect of clopidogrel and ticlopidine. J Pharmacol Exp Ther 1994;269:772-777.
20. Di Minno G, Cerbone AM, Mattioli PL, et al. Functionally thrombasthenic state in normal platelets following the administration of ticlopidine. J Clin Invest 1985;75:328-338.
21. Lecrubier C, Conard J, Horellow MH, et al. Study of platelet aggregation induced by platelet activating factor (PAF) after administration of ticlopidine or aspirin. Agents Actions Suppl 1983;13:77-80.
22. Meyer D, Pietu G, Fressinaud E, et al. Von Willebrand factor: structure and function. Mayo Clin Proc 1991;66:516-523.
23. Cattaneo M, Lombardi R, Bettega D, et al. Shear-induced platelet aggregation is potentiated by desmopressin and inhibited by ticlopidine. Arterioscler Thromb Vasc Biol 1993;13:393-397.
24. Greene CE. Effects of aspirin and propranolol on feline platelet aggregation. Am J Vet Res 1985;46:1820-1823.
25. Allen DG, Johnstone IB, Crane S. Effects of aspirin and propranolol alone and in combination on hemostatic determinants in the healthy cat. Am J Vet Res 1985;46:660-663.
26. Behrend EN, Grauer GF, Greco DS, et al. Comparison of the effects of diltiazem and aspirin on platelet aggregation in cats. J Am Anim Hosp Assoc 1996;32:11-18.
27. Boudreaux MK, Weiss RC, Toivio-Kinnucan M, et al. Potentiation of platelet responses in vitro by feline infectious peritonitis virus. Vet Pathol 1990;27:261-268.
28. Picard-Fraire C. Ticlopidine hydrochloride: relationship between dose, kinetics, plasma concentration and effect on platelet function. Thromb Res Suppl 1983;4:119-128.
29. Desager JP. Clinical pharmacokinetics of ticlopidine. Clin Pharmacokinet 1994;26:347-355.
30. Shah J, Teitelbaum P, Molony B, et al. Single and multiple dose pharmacokinetics of ticlopidinc in young and elderly subjects. Br J Clin Pharmacol 1991;32:761-764.
31. Imhoff RK. Production of aortic occlusion resembling acute aortic embolism syndrome in cats. Nature 1961;192:979-984.
32. Cattaneo M, Winocour PD, Somers DA, et al. Effect of ticlopidine on platelet aggregation, adherence to damaged vessels, thrombus formation and platelet survival. Thromb Res Suppl 1985;37:29-43.
33. Knudsen JB, Gormsen J. The effect of ticlopidine on platelet function in normal volunteers and in patients with platelet hyperaggregability in vitro. Thromb Res Suppl 1979;16:663-671.
34. Boudreaux MK, Jeffers C, Lipscomb D, et al. The effect of ticlopidine on canine platelets, fibrinogen, and antithrombin III activity. J Vet Pharmacol Ther 1992;15:1-9.
35. Boudreaux MK, Dillon AR, Sartin EA, et al. Effects of treatment with ticlopidine in heartworm-negative, heartworm-infected, and embolized heartworm-infected dogs. Am J Vet Res 1991;52:2000-2006.
36. Yang LH, Hoppensteadt D, Fareed J. Modulation of vasoconstriction by clopidogrel and ticlopidine. Thromb Res Suppl 1998; 92:83-89.
37. Bennett CL, Weinberg PD, Rozenberg K, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine: a review of